On day 28 after infusion, they achieved a CR rate of 83.3%, without dose‐limiting toxicity, ICANS, or genome editing‐associated adverse events.[82] Other efforts against BCMA+ r/r multiple myeloma,[83] CD19+ children with refractory B cell leukemia,[84] and CD7+ ALL[85] have been reported in recent years. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.